Drug intelligence / Profile preview

Xingqi Xiaoying Granule

Development stage: Unknown
Lead developer: Shaanxi Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Xingqi Xiaoying Granule is a Traditional Chinese Medicine (TCM) hospital preparation developed by the Shaanxi Provincial Hospital of Traditional Chinese Medicine. It is specifically designed to treat Hashimoto's thyroiditis (HT) characterized by the TCM syndrome of 'qi stagnation and phlegm obstruction.' The formulation aims to alleviate clinical symptoms, reduce thyroid volume, and lower serum levels of thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TgAb). By promoting qi circulation and resolving phlegm, it addresses the underlying TCM pathology associated with thyroid enlargement and autoimmune dysfunction.

Other names: Xingqi Xiaoying Keli

Beyond the preview

Go deeper on Xingqi Xiaoying Granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xingqi Xiaoying Granule.

Explore the full profile